- Home
- PCN vs MGTX Comparison
PCN vs MGTX Comparison
Compare PCN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCN
- MGTX
- Stock Information
- Founded
- PCN 2001
- MGTX 2015
- Country
- PCN United States
- MGTX United States
- Employees
- PCN N/A
- MGTX N/A
- Industry
- PCN Investment Managers
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCN Finance
- MGTX Health Care
- Exchange
- PCN Nasdaq
- MGTX Nasdaq
- Market Cap
- PCN 838.1M
- MGTX 744.9M
- IPO Year
- PCN N/A
- MGTX N/A
- Fundamental
- Price
- PCN $12.69
- MGTX $7.55
- Analyst Decision
- PCN
- MGTX Strong Buy
- Analyst Count
- PCN 0
- MGTX 6
- Target Price
- PCN N/A
- MGTX $23.83
- AVG Volume (30 Days)
- PCN 218.7K
- MGTX 542.0K
- Earning Date
- PCN 01-01-0001
- MGTX 11-13-2025
- Dividend Yield
- PCN 9.73%
- MGTX N/A
- EPS Growth
- PCN N/A
- MGTX N/A
- EPS
- PCN N/A
- MGTX N/A
- Revenue
- PCN N/A
- MGTX $27,417,000.00
- Revenue This Year
- PCN N/A
- MGTX $110.63
- Revenue Next Year
- PCN N/A
- MGTX $212.13
- P/E Ratio
- PCN N/A
- MGTX N/A
- Revenue Growth
- PCN N/A
- MGTX 96.83
- 52 Week Low
- PCN $10.70
- MGTX $4.55
- 52 Week High
- PCN $14.48
- MGTX $9.73
- Technical
- Relative Strength Index (RSI)
- PCN 44.93
- MGTX 38.12
- Support Level
- PCN $12.24
- MGTX $7.30
- Resistance Level
- PCN $12.96
- MGTX $7.86
- Average True Range (ATR)
- PCN 0.13
- MGTX 0.67
- MACD
- PCN -0.01
- MGTX -0.12
- Stochastic Oscillator
- PCN 59.37
- MGTX 11.52
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.